Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey
Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice. Methods: We restrospectively reviewed our database on tolvaptan as an add-on treatment in hypervolemic p...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KARE Publishing
2017-07-01
|
| Series: | Türk Kardiyoloji Derneği Arşivi |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-80026 |
| _version_ | 1797920264149794816 |
|---|---|
| author | Saim Sağ Aysel Aydin Kaderli Abdülmecit Yildiz Bülent Cuma Gül Bülent Özdemir Ibrahim Baran Sümeyye Güllülü Ali Aydınlar Yüksel Çavuşoğlu |
| author_facet | Saim Sağ Aysel Aydin Kaderli Abdülmecit Yildiz Bülent Cuma Gül Bülent Özdemir Ibrahim Baran Sümeyye Güllülü Ali Aydınlar Yüksel Çavuşoğlu |
| author_sort | Saim Sağ |
| collection | DOAJ |
| description | Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice.
Methods: We restrospectively reviewed our database on tolvaptan as an add-on treatment in hypervolemic patients admitted to our clinic due to deterioration of HF and having hyponatremia resistant to standard therapy. Severe hyponatremia was defined as serum sodium concentration ≤125 mEq/L. The database included demographic, clinical, laboratory, and echocardiographic findings on admission, and numerous outcome measures for oral tolvaptan treatment were used to assess its efficacy and safety.
Results: The study group consisted of 56 hypervolemic HF patients with severe hyponatremia (25 female and 31 male) with mean age of 66 years. All patients received a single dose of tolvaptan 15 mg daily for an average of 3.2 days due to severe hyponatremia. Sodium and potassium concentrations, fluid intake, and urine volume increased (p<0.0001, p=0.037, p<0.0001, and p<0.0001, respectively), whereas furosemide dosage, body weight, heart rate, systolic and diastolic blood pressure, and New York Heart Association class decreased significantly in response to tolvaptan treatment, without a rise in serum creatinine or urea concentrations (p<0.0001, p<0.0001, p=0.001, p<0.049, p<0.009 ve p=0.001, respectively).
Conclusion: In this retrospective, single-centered study conducted in a small group of Turkish patients, short-term treatment with low-dose tolvaptan added to standard therapy of hypervolemic HF patients with severe hyponatremia was well tolerated with a low rate of major side effects and was effective in correcting severe hyponatremia. |
| first_indexed | 2024-04-10T13:58:22Z |
| format | Article |
| id | doaj.art-0eb87de9899844388ffb4b3cf9eaa867 |
| institution | Directory Open Access Journal |
| issn | 1016-5169 |
| language | English |
| last_indexed | 2024-04-10T13:58:22Z |
| publishDate | 2017-07-01 |
| publisher | KARE Publishing |
| record_format | Article |
| series | Türk Kardiyoloji Derneği Arşivi |
| spelling | doaj.art-0eb87de9899844388ffb4b3cf9eaa8672023-02-15T16:10:20ZengKARE PublishingTürk Kardiyoloji Derneği Arşivi1016-51692017-07-0145541542510.5543/tkda.2017.80026TKDA-80026Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in TurkeySaim Sağ0Aysel Aydin Kaderli1Abdülmecit Yildiz2Bülent Cuma Gül3Bülent Özdemir4Ibrahim Baran5Sümeyye Güllülü6Ali Aydınlar7Yüksel Çavuşoğlu8Department of Cardiology, Uludag University, Bursa, TurkeyDepartment of Cardiology, Uludag University, Bursa, TurkeyDepartment of Nephrology, Uludag University, Bursa, TurkeyDepartment of Nephrology, Uludag University, Bursa, TurkeyDepartment of Cardiology, Uludag University, Bursa, TurkeyDepartment of Cardiology, Uludag University, Bursa, TurkeyDepartment of Cardiology, Uludag University, Bursa, TurkeyDepartment of Cardiology, Uludag University, Bursa, TurkeyDepartment of Cardiology, Eskisehir Osmangazi University, Eskisehir, TurkeyObjective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice. Methods: We restrospectively reviewed our database on tolvaptan as an add-on treatment in hypervolemic patients admitted to our clinic due to deterioration of HF and having hyponatremia resistant to standard therapy. Severe hyponatremia was defined as serum sodium concentration ≤125 mEq/L. The database included demographic, clinical, laboratory, and echocardiographic findings on admission, and numerous outcome measures for oral tolvaptan treatment were used to assess its efficacy and safety. Results: The study group consisted of 56 hypervolemic HF patients with severe hyponatremia (25 female and 31 male) with mean age of 66 years. All patients received a single dose of tolvaptan 15 mg daily for an average of 3.2 days due to severe hyponatremia. Sodium and potassium concentrations, fluid intake, and urine volume increased (p<0.0001, p=0.037, p<0.0001, and p<0.0001, respectively), whereas furosemide dosage, body weight, heart rate, systolic and diastolic blood pressure, and New York Heart Association class decreased significantly in response to tolvaptan treatment, without a rise in serum creatinine or urea concentrations (p<0.0001, p<0.0001, p=0.001, p<0.049, p<0.009 ve p=0.001, respectively). Conclusion: In this retrospective, single-centered study conducted in a small group of Turkish patients, short-term treatment with low-dose tolvaptan added to standard therapy of hypervolemic HF patients with severe hyponatremia was well tolerated with a low rate of major side effects and was effective in correcting severe hyponatremia.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-80026aquaretic treatmentcongestive heart failurehyponatremiatolvaptan |
| spellingShingle | Saim Sağ Aysel Aydin Kaderli Abdülmecit Yildiz Bülent Cuma Gül Bülent Özdemir Ibrahim Baran Sümeyye Güllülü Ali Aydınlar Yüksel Çavuşoğlu Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey Türk Kardiyoloji Derneği Arşivi aquaretic treatment congestive heart failure hyponatremia tolvaptan |
| title | Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey |
| title_full | Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey |
| title_fullStr | Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey |
| title_full_unstemmed | Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey |
| title_short | Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey |
| title_sort | use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia the initial experience at a single center in turkey |
| topic | aquaretic treatment congestive heart failure hyponatremia tolvaptan |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-80026 |
| work_keys_str_mv | AT saimsag useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey AT ayselaydinkaderli useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey AT abdulmecityildiz useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey AT bulentcumagul useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey AT bulentozdemir useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey AT ibrahimbaran useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey AT sumeyyegullulu useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey AT aliaydınlar useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey AT yukselcavusoglu useoftolvaptaninpatientshospitalizedforworseningchronicheartfailurewithseverehyponatremiatheinitialexperienceatasinglecenterinturkey |